NASDAQ:GENE Genetic Technologies (GENE) Stock Price, News & Analysis → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Free GENE Stock Alerts Notice: Trading of Genetic Technologies halted at 12:18 PM EST due to "LULD pause". $2.44 -0.72 (-22.78%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$2.30▼$3.2050-Day Range$1.90▼$3.3652-Week Range$1.80▼$5.90Volume88,022 shsAverage Volume28,918 shsMarket Capitalization$9.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Genetic Technologies alerts: Email Address Ad Paradigm PressAI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About Genetic Technologies Stock (NASDAQ:GENE)Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.Read More GENE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GENE Stock News HeadlinesApril 18, 2024 | msn.comGenetic Technologies stock tumbles on direct offering pricingApril 18, 2024 | globenewswire.comGenetic Technologies Announces $2 Million Registered Direct OfferingApril 18, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 13, 2024 | americanbankingnews.comGenetic Technologies (NASDAQ:GENE) Stock Passes Above Two Hundred Day Moving Average of $2.72April 11, 2024 | msn.comBeethoven's DNA Unravels a Musical Mystery: Genetic Paradox UncoveredApril 4, 2024 | washingtonpost.comAuthorities identify remains of man who went missing in Niagara Falls in 1990 and drifted 145 milesApril 4, 2024 | msn.comNew Kaiser genomics lab uses robots for faster, cheaper routine genetic testsApril 3, 2024 | msn.comMicrobes’ activities underground are no longer a mystery thanks to new technologyApril 18, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 2, 2024 | finance.yahoo.comGenetic Technologies’ Digital Strategy Ignites Significant Traction in US MarketApril 2, 2024 | globenewswire.comGenetic Technologies' Digital Strategy Ignites Significant Traction in US MarketMarch 30, 2024 | msn.comAdvancing cancer care with emerging technology: A fine balanceMarch 29, 2024 | msn.comUnveiling the Genetic Mysteries of Tiny Ant Queens Insights from Supergene ResearchMarch 28, 2024 | msn.comNew genetic system analyzes the underlying mechanisms of CRISPR-based DNA repair outcomesMarch 28, 2024 | msn.comSweet success: Researchers crack sugarcane's complex genetic codeMarch 28, 2024 | msn.comUnveiling Genetic Risks A New Tool for Tracking CRISPR EditsMarch 28, 2024 | msn.comExploring Beethoven’s Genetic Code: A Clue to the Mystery of Musical TalentMarch 28, 2024 | msn.comNew genetic analysis tool tracks risks tied to CRISPR editsMarch 25, 2024 | finance.yahoo.comGENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised HealthcareMarch 18, 2024 | msn.comAI Tool Demonstrates High Accuracy in Genetic Counseling QuestionsMarch 18, 2024 | msn.comGenetic basis for the evolution of hair discovered in the clawed frogMarch 14, 2024 | msn.comAustralian Timor ponies have genetic diversity necessary for a breeding program, researchers findMarch 14, 2024 | msn.comResearch reveals the genetic code behind non-identical twinsMarch 13, 2024 | msn.comUnveiling the Genetic Bottleneck Theory: Insights into Mercedes-Benz’s EvolutionMarch 12, 2024 | msn.comUncovering the Genetic Diversity of GiraffesMarch 12, 2024 | msn.comThe genetic ‘crystal ball’: Would you want to know which disease will kill you?March 12, 2024 | msn.comVirtual tool for studying gene function aims to reduce number of animals used for genetic testingSee More Headlines Receive GENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/18/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GENE CUSIPN/A CIK1166272 Webwww.gtgcorporate.com Phone(138) 412-7000Fax011-61-3-8412-7040Employees60Year Founded1989Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.02 Current Ratio1.67 Quick Ratio1.55 Sales & Book Value Annual Sales$5.85 million Price / Sales1.61 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book1.25Miscellaneous Outstanding Shares3,850,000Free Float3,598,000Market Cap$9.39 million OptionableOptionable Beta1.14 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Simon MorrissChief Executive OfficerMr. Tony Di Pietro AGIAB.Com, C.A., CPA, M.A.I.C.D., CFO & Company SecretaryMr. Carl S. Stubbings BScChief Commercial OfficerMr. Kevin CamilleriChief Executive Officer of EasyDNAMr. Paul Keith Mathieson Viney B. BusFCI, FCPA, FGIA, ConsultantKey CompetitorsOrganovoNASDAQ:ONVOSorrento TherapeuticsNASDAQ:SRNECoeptis TherapeuticsNASDAQ:COEPSenti BiosciencesNASDAQ:SNTIInhibikase TherapeuticsNYSE:IKTView All Competitors GENE Stock Analysis - Frequently Asked Questions How have GENE shares performed in 2024? Genetic Technologies' stock was trading at $2.40 at the beginning of the year. Since then, GENE shares have increased by 1.7% and is now trading at $2.44. View the best growth stocks for 2024 here. Are investors shorting Genetic Technologies? Genetic Technologies saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 11,500 shares, a decrease of 58.5% from the March 15th total of 27,700 shares. Based on an average daily volume of 27,000 shares, the short-interest ratio is presently 0.4 days. View Genetic Technologies' Short Interest. When did Genetic Technologies' stock split? Genetic Technologies shares reverse split on Monday, December 4th 2023. The 1-5 reverse split was announced on Monday, December 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Genetic Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Inovio Pharmaceuticals (INO), Novavax (NVAX), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Atossa Therapeutics (ATOS), FuelCell Energy (FCEL) and Heat Biologics (HTBX). How do I buy shares of Genetic Technologies? Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GENE) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[Urgent!] Generational Wealth GameplanCrypto 101 MediaBiden’s $374B Giveaway Into This SectorDTIDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Next Nvidia?InvestorPlaceHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genetic Technologies Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.